Stockscreener 앱 받기
32.63
2.22%
0.71
시장 영업 전:
32.12
-0.51
-1.56%
Avidity Biosciences Inc 주식(RNA)의 최신 뉴스
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely - Yahoo Finance
How to Take Advantage of moves in (RNA) - Stock Traders Daily
Avidity Biosciences (NASDAQ:RNA) Stock Price Up 6%Here's Why - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Avidity Biosciences CEO Sarah Boyce sells $297k in stock - MSN
Avidity Biosciences' chief medical officer sells shares totaling $112,856 - MSN
Assenagon Asset Management S.A. Invests $1.18 Million in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $84,611 in stock - MSN
Avidity Biosciences chief scientific officer sells shares worth $162,191 - MSN
Avidity Biosciences director sells $53,536 in stock - MSN
Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 3,287 Shares - MarketBeat
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 2,959 Shares of Stock - MarketBeat
Sarah Boyce Sells 10,397 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock - MarketBeat
Avidity Biosciences CHRO Teresa McCarthy sells $84,611 in stock By Investing.com - Investing.com Canada
Arthur A. Levin Sells 1,872 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock - MarketBeat
Avidity Biosciences director sells $53,536 in stock By Investing.com - Investing.com Canada
Avidity Biosciences CFO sells $93,985 in stock By Investing.com - Investing.com Canada
Avidity Biosciences chief program officer sells shares worth $206,799 By Investing.com - Investing.com Canada
Avidity Biosciences' chief medical officer sells shares totaling $112,856 By Investing.com - Investing.com Australia
Avidity Biosciences chief program officer sells shares worth $206,799 - Investing.com
Avidity Biosciences CEO Sarah Boyce sells $297k in stock By Investing.com - Investing.com UK
Analysts Offer Predictions for RNA FY2025 Earnings - MarketBeat
Leerink Partnrs Has Negative Estimate for RNA Q1 Earnings - MarketBeat
Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Exciting News from Avidity Biosciences! New Opportunities Await! - Qhubo
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com
Avidity Biosciences Awards New Employee Stock Options and RSUs Worth $304K - StockTitan
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential - Insider Monkey
Avidity Set To File First Of Three Muscular Dystrophy Drugs In 2025 - News & Insights
Avidity Biosciences Inc (RNA-Q) QuotePress Release - The Globe and Mail
Avidity Biosciences Becomes Oversold (RNA) - Nasdaq
Avidity Biosciences (NASDAQ:RNA) Sees Large Volume IncreaseHere's Why - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Given Buy Rating at HC Wainwright - MarketBeat
Analyst Expectations For Avidity Biosciences's Future - Benzinga
JPMorgan Chase & Co. Has $21.45 Million Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences, Inc. Announces 2025 Upcoming Clinical and Regulatory Highlights - Marketscreener.com
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 - PR Newswire
Avidity Biosciences Awards $31.42 Stock Options to New Chief Technical Officer - StockTitan
Principal Financial Group Inc. Reduces Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $64.36 Average Target Price from Analysts - MarketBeat
Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now? - Insider Monkey
Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth - Simply Wall St
12 Best Multibagger Stocks to Buy Right Now - Insider Monkey
Avidity Biosciences (NASDAQ:RNA) Trading Down 5.4%What's Next? - MarketBeat
5.49%
0.79%
자본화:
|
볼륨(24시간):